Nrx Pharmaceuticals, INC 8-K filings

NRx Pharmaceuticals reports progress on its preservative-free ketamine ANDA, with the FDA identifying no major drug-component deficiencies but requesting clarification on vial packaging.

NRx Pharmaceuticals' subsidiary, NRX Defense Systems, has been selected by DARPA for negotiation of a potential award for a clinical trial combining D-cycloserine with Transcranial Magnetic Stimulation.

NRx Pharmaceuticals has successfully closed an underwritten public offering of common stock, raising approximately $22.3 million in gross proceeds.

NRx Pharmaceuticals has announced its intention to conduct an underwritten public offering of its common stock to support working capital and general corporate growth.

NRx Pharmaceuticals' stockholders approved an amendment to its Omnibus Incentive Plan, significantly increasing the annual share reserve for equity awards.

NRx Pharmaceuticals announced a clear path to full New Drug Application approval for NRX-100, expanding its target indication and leveraging Real World Data following a Type C FDA meeting.

NRx Pharmaceuticals, Inc. filed a prospectus supplement for an At-The-Market offering of up to $20 million in common stock.

NRx Pharmaceuticals, Inc. announced the appointment of Joseph M. Casper, a veteran with 35 years of healthcare industry experience, as its new Chief Operating Officer, effective January 27, 2026.

NRx Pharmaceuticals announced its 2025 Annual Meeting date and record date, while also disclosing a Nasdaq non-compliance notice for failing to hold the meeting within the required timeframe.

NRx Pharmaceuticals announced the full repayment of its remaining $5.4 million balance sheet debt to Anson Funds through an equity conversion, achieving a debt-free balance sheet.

NRX Pharmaceuticals, Inc. announced a change in its independent registered public accounting firm, dismissing Salberg & Company P.A. and engaging Weinberg & Company P.A.

NRx Pharmaceuticals, Inc. filed an amended 8-K to include the financial statements of Dura Medical, LLC, acquired on September 8, 2025, and pro forma combined financials.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has acquired a strategic interest in Cohen & Associates, a leading interventional psychiatry clinic, and appointed Dr. Rebecca Cohen as Medical Director.

NRx Pharmaceuticals announced FDA approval of a Suitability Petition for its single-patient, preservative-free ketamine product, KETAFREE, paving the way for an immediate ANDA re-filing.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has completed the acquisition of Dura Medical, expanding its interventional psychiatry clinic network across Florida's West Coast.

NRx Pharmaceuticals announced plans for its HOPE Therapeutics clinics rollout in Fall 2025, featuring a unique residential program for mental health, and disclosed an $8.8 million capital raise.

NRx Pharmaceuticals announced a $6.5 million capital raise and an expanded FDA Fast Track Designation for its lead drug candidate, NRX-100, alongside progress in its clinic network.

NRx Pharmaceuticals received FDA Fast Track designation for NRX-100 for suicidal ideation in depression, while also addressing minor deficiencies in its Abbreviated New Drug Approval application.

NRx Pharmaceuticals, Inc. has announced the filing of its Abbreviated New Drug Application (ANDA) for NRX-100, a preservative-free IV ketamine formulation, aiming to address a critical US drug shortage and capture a significant share of the growing ketamine market.

NRx Pharmaceuticals announced its Q1 2025 financial results, progress in regulatory filings for NRX-100 and NRX-101, and HOPE Therapeutics secured $7.8 million in debt financing to support clinic acquisitions.

NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute, a leading clinic and research site, to bolster its network of interventional psychiatry clinics.

NRx Pharmaceuticals has increased the maximum aggregate offering price of its common stock under the At the Market Offering Agreement to $20 million.

NRx Pharmaceuticals announces financial results for Q4 and full year 2024, highlighting progress in drug development and strategic initiatives.

NRx Pharmaceuticals has entered into a second amended agreement to sell shares and pursue a $25 million investment in its subsidiary, HOPE Therapeutics, for acquisitions of interventional psychiatry clinics.

NRx Pharmaceuticals announces an $8.9 million financing agreement with Anson Funds, including above-market equity and senior secured debt, to support clinical development and the launch of HOPE Therapeutics.

NRx Pharmaceuticals has successfully regained compliance with Nasdaq's minimum market value of listed securities requirement, ensuring its continued listing on the Nasdaq Capital Market.

Janet Rehnquist resigned from the Board of Directors of NRx Pharmaceuticals, effective immediately, with Sauer Nunes entitled to designate a replacement following a term sheet execution.

NRx Pharmaceuticals and its subsidiary, HOPE Therapeutics, have entered into a binding term sheet with Smith & Sauer, LLC for a $27 million investment to fund clinic acquisitions and pharmaceutical operations.

NRx Pharmaceuticals has appointed Michael Abrams as its new Chief Financial Officer, succeeding interim CFO Richard Narido.

NRx Pharmaceuticals announced a significant reduction in operating losses, progress in drug development for suicidal ideation, and the acquisition of psychiatric clinics through its subsidiary HOPE Therapeutics.